<SEC-DOCUMENT>0001140361-23-007713.txt : 20230221
<SEC-HEADER>0001140361-23-007713.hdr.sgml : 20230221
<ACCEPTANCE-DATETIME>20230221060400
ACCESSION NUMBER:		0001140361-23-007713
CONFORMED SUBMISSION TYPE:	DFAN14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230221
DATE AS OF CHANGE:		20230221

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		23645095

	BUSINESS ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		SPACES SOUTH DOCKLANDS, BLOCK C
		STREET 2:		77 SIR JOHN ROGERSON'S QUAY
		CITY:			DUBLIN 2
		STATE:			L2
		ZIP:			D02 VK60

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sarissa Capital Management LP
		CENTRAL INDEX KEY:			0001577524
		IRS NUMBER:				900924432
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DFAN14A

	BUSINESS ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
		BUSINESS PHONE:		203-302-2330

	MAIL ADDRESS:	
		STREET 1:		660 STEAMBOAT ROAD
		CITY:			GREENWICH
		STATE:			CT
		ZIP:			06830
</SEC-HEADER>
<DOCUMENT>
<TYPE>DFAN14A
<SEQUENCE>1
<FILENAME>ny20006859x26_dfan14a.htm
<DESCRIPTION>DFAN14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions
         Document created using Broadridge PROfile 23.1.2.5118
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><font style="font-size: 14pt;">UNITED STATES<br>
        SECURITIES AND EXCHANGE COMMISSION</font><br>
      <font style="font-size: 12pt;">Washington, D.C. 20549</font></div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-size: 18pt;">SCHEDULE 14A</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center;"><font style="font-weight: bold;">Proxy Statement Pursuant to Section&#160;14(a) of the<br>
        Securities Exchange Act of 1934<br>
      </font><font style="font-family: 'Times New Roman',Times,serif;"><br>
      </font></div>
    <div>Filed by the Registrant&#160;&#160; &#9744;</div>
    <div>Filed by a party other than the Registrant&#160;&#160; &#9746;</div>
    <div>Check the appropriate box:</div>
    <div>&#9744;&#160; &#160; <font style="font-family: 'Times New Roman',Times,serif;">Preliminary Proxy Statement</font></div>
    <div>&#9744;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></div>
    <div>&#9744;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Definitive Proxy Statement</font></div>
    <div>&#9746;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Definitive Additional Materials</font></div>
    <div>&#9744;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Soliciting Material under &#167; 240.14a-12</font></div>
    <div><font style="font-family: 'Times New Roman',Times,serif;"> <br>
      </font></div>
    <div style="text-align: center; font-weight: bold;"><font style="font-size: 24pt;">Amarin Corporation plc </font>
      <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div>
      <div style="text-align: center;">(Name of Registrant as Specified In Its Charter)</div>
      <div style="font-family: 'Times New Roman',Times,serif;"><br>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Catapult Fund LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Hawkeye Fund LP</div>
    <div style="text-align: center; font-weight: bold;">ISP Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Offshore Master Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Master Fund II LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Athena Fund Ltd</div>
    <div style="text-align: center; font-weight: bold;">Atom Master Fund LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Fund GP LP</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Fund GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Offshore Fund GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Management GP LLC</div>
    <div style="text-align: center; font-weight: bold;">Sarissa Capital Management LP</div>
    <div style="text-align: center; font-weight: bold;">Alexander J. Denner, Ph.D.</div>
    <div style="text-align: center; font-weight: bold;">Patrice Bonfiglio</div>
    <div style="text-align: center; font-weight: bold;">Paul Cohen, M.D.<br>
      Mark DiPaolo<br>
      Keith L. Horn<br>
      Odysseas Kostas, M.D.</div>
    <div style="text-align: center; font-weight: bold;">Louis Sterling III<br>
      Diane E. Sullivan
      <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div>
      <div style="text-align: center;">&#160;(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>
      <div style="font-family: 'Times New Roman',Times,serif;"><br>
      </div>
    </div>
    <div>Payment of Filing Fee (Check all boxes that apply):</div>
    <div>&#9746;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">No fee required</font></div>
    <div>&#9744;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Fee paid previously with preliminary materials</font></div>
    <div>&#9744;&#160;&#160;&#160; <font style="font-family: 'Times New Roman',Times,serif;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</font></div>
    <div style="font-family: 'Times New Roman',Times,serif;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>This filing contains a press release issued on February 20, 2023 by Sarissa Capital.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <br>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SARISSA CAPITAL URGES AMARIN SHAREHOLDERS TO VOTE </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#8220;FOR&#8221; NECESSARY CHANGE</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Sarissa believes Amarin leadership will continue to destroy shareholder value during this </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">critical period; We cannot afford to maintain the status quo</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Sarissa has a stellar track record of success and its nominees have the experience and </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">qualifications to help fix the problems at Amarin</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Greenwich, CT, February 20, 2023 &#8211; Sarissa Capital Management LP (&#8220;Sarissa&#8221;) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Sarissa urges Amarin shareholders to vote &#8220;FOR&#8221; necessary change at our upcoming shareholder meeting. The outcome of this meeting will significantly affect the future of Amarin. The decision is
      one of maintaining the status quo with the current regime which has overseen a tremendous destruction of shareholder value or remaking Amarin for the benefit of shareholders.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Amarin has a uniquely valuable drug Vascepa/Vazkepa that can meaningfully reduce cardiovascular events in patients and save significant resources for health systems worldwide. This highly
      beneficial and rare profile of Vascepa/Vazkepa has been significantly underutilized by the current regime. Amarin is at a critical juncture where strategic decisions must be made by a board that seeks to leverage the strengths of the company&#8217;s assets
      for the benefit of shareholders. Unfortunately, the current leadership has a history of operational blunders and poor capital allocation decisions. Even more disappointing, the current regime repeatedly attempts to obfuscate the truth with many
      misstatements about their performance and Sarissa&#8217;s stellar track record of success in order to secure votes.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Sarissa did not engage in this proxy contest lightly. We were compelled to do so after witnessing egregious corporate governance and experiencing the painful collapse of the share price, like
      other shareholders. As Amarin&#8217;s largest shareholder with a history of value creation in the cardiovascular space, Sarissa believes it can help fix the company&#8217;s problems and unlock the true potential of Amarin with its nominees on the board. We have
      a stellar track record of success with the average performance of our portfolio companies during the tenure of Sarissa and Sarissa designees being +39.7%.* In contrast, Amarin&#8217;s performance under CEO Karim Mikhail and Chairman Per Wold-Olsen were
      -70.8% and -62.8% respectively.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8224;</sup> We believe current Amarin leadership should be accountable to shareholders, the owners of the company, for their poor performance.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">We cannot afford to allow the current regime to destroy further shareholder value. Our slate includes Sarissa candidates that helped turn around The Medicines Company until its ultimate sale for
      nearly $10 billion. We have the qualifications and the experience to help guide Amarin through this critical period.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Please see our latest presentation published February 17, 2023: <u>https://freeamarin.com/wp-content/pdfs/vote-for-change.pdf</u></div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">We urge all shareholders to vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the Sarissa Nominees and &#8220;<font style="font-weight: bold;">FOR</font>&#8221; the removal of Chairman Per Wold-Olsen on or
      prior to the deadline on Tuesday, February 21, 2023.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">You can vote on the blue proxy card or the white proxy card but if you want to fully support Sarissa, you must make sure that all &#8220;<font style="font-weight: bold;">FOR</font>&#8221; boxes are marked on
      your proxy card (blue or white) before you submit it.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">If you have any questions on how to vote, we recommend that you contact Sarissa&#8217;s proxy solicitor, D.F. King, by calling (800) 331-7024 or emailing <u>AMRN@dfking.com</u>.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Visit our website at <u>www.freeamarin.com</u><u>&#160;</u>for helpful information about Sarissa and the need for change at Amarin.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">IF YOU ALREADY VOTED &#8220;FOR&#8221; ALL PROPOSALS AND SUBMITTED YOUR BLUE PROXY CARD, THERE IS NOTHING ELSE YOU NEED TO DO TO SUPPORT SARISSA&#8217;S NOMINEES. YOU DO NOT NEED TO VOTE AGAIN.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">The General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, <font style="font-weight: bold;"><u>SUBMIT YOUR VOTE ON OR BEFORE TUESDAY,
          FEBRUARY 21, 2023</u></font>.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">* Calculated as average price change where a Sarissa or Sarissa-affiliated director held tenure as a board member, for larger Sarissa portfolio positions defined as (&#8805;$50M), between the date
      immediately preceding their first date-in service and 12/30/2022. Not weighted by investment and not indicative of Sarissa&#8217;s investment returns.</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#8224; Calculated as price change between the dates 7/30/2021 and 12/30/2022 for CEO Karim Mikhail and 1/7/2022 and 12/30/2022 for Per Wold-Olsen.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Additional Information</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in
      connection with the solicitation of shareholders of Amarin Corporation plc (the &#8220;Company&#8221;) at the general meeting of the Company for the election of Sarissa Capital&#8217;s slate of highly-qualified nominees (the &#8220;General Meeting&#8221;). Shareholders are
      advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">The definitive proxy statement and other relevant documents are available at no charge on the SEC&#8217;s website at <u>www.sec.gov</u> and at <u>www.freeamarin.com</u>. The definitive proxy
      statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital&#8217;s proxy solicitor, D.F. King &amp; Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).</div>
    <div><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">#FreeAmarin</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze8aa14c151f94b11ba310a0198ef0b66" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">Contact:</td>
          <td style="width: auto; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Jean Puong<br>
              Sarissa Capital Management LP<br>
              <u>info@sarissacap.com</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
